After A 30% Fall In A Year, Is Pfizer Stock A Better Pick Over Merck?

Published on 2 Apr 2024 on Forbes

We think that this gap in valuation multiple will narrow in favor of Pfizer.

Read the rest of the article

Start tracking your investments with Statfolio

Merck & Co. (NYSE: MRK) has presented new data from its Phase 3 STRIDE-10 trial of V116, an...

Investing.com 29 Apr 2024

Understanding Merck KGaA's Upcoming Dividend Payout and Financial Health Merck KGaA (MKKGY) recen...

GuruFocus.com via Yahoo Finance 29 Apr 2024

Huma Therapeutics ("Huma"), a leader in global digital health innovation, together with Merck KGa...

FOX 23 News Albany 29 Apr 2024

The board of Merck KGaA (ETR:MRK) has announced that it will pay a dividend of €2.20 per share on...

Simply Wall St. via Yahoo Finance 28 Apr 2024

Merck & Co., Inc. (NYSE:MRK) just released its quarterly report and things are looking bullish. T...

Simply Wall St. via Yahoo Finance 27 Apr 2024

Pharma giants Merck and Bristol-Myers Squibb are both getting ready for some of their key drug...

Quartz 25 Apr 2024

Merck Stock Gains On Its Blockbuster Cancer Drug Keytruda, Raises Annual Outlook On Thursday, U.S...

Benzinga via Yahoo Finance 25 Apr 2024

Merck's bread-and-butter cancer drug grew by double digits again in the first quarter.

Investor's Business Daily 25 Apr 2024

Investing.com 25 Apr 2024

For the quarter ended March 2024, Merck (MRK) reported revenue of $15.78 billion, up 8.9% over th...

Zacks via Yahoo Finance 25 Apr 2024